Finland· FI-REL-REL6711
Myleran
A busulfan product, registered in Finland by The Wellcome Foundation Limited. The same ATC class is registered in 15 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Busulfan is registered in 15 of 19 countries.
Countries holding a registration under ATC L01AB01 (busulfan), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Busulfan · ATC L01AB01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Manufacturer
- The Wellcome Foundation Limited
- Country
- Finland (FI)
- ATC code
- L01AB01
- ATC class
- Busulfan
- Defined daily dose
- 0.224 g, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
245 interactions on record for busulfan.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Busulfan · interactions on record
245 records
- 34 severe
- 141 moderate
- 16 minor
- 54 info
Most severe, free to view
- Nalidixic acidJ01MB02severe
- MetronidazoleJ01XD01severe
- ThiotepaL01AC01severe
- CladribineL01BB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01AB01
Busulfan, as other registers publish it.
- FinlandBusilvexPierre Fabre Medicament
- DenmarkBusilvexPierre Fabre Medicament
- BelgiumBusilvex 6 mg/mlPierre Fabre Médicament
- FranceBUSILVEX 6 mg/ml, solution à diluer pour perfusionPIERRE FABRE MEDICAMENT
- United KingdomBusilvex 60mg/10ml concentrate for solution for infusion ampoulesPierre Fabre Ltd
- United StatesBusulfanSagent Pharmaceuticals
- United StatesBusulfanPharmascience Inc.
- United StatesBusulfanAccord Healthcare, Inc
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fc21e5d8-45ce-4145-98ea-d96a46f1728d GET /v1/drugs/fc21e5d8-45ce-4145-98ea-d96a46f1728d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "tabletti",
"route": null,
"ddd_unit": null,
"strength": "2 mg",
"atc_label": "busulfaani",
"ma_number": "851",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL6711",
"authorised_at": "1965-01-27"
}See everything about busulfan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.